FAQ on Calidi Biotherapeutics Inc.'s New CEO Appointment

Who has been appointed as the new CEO of Calidi Biotherapeutics Inc.?

Dr. Eric Poma has been appointed as the new Chief Executive Officer of Calidi Biotherapeutics Inc., bringing over 30 years of experience in the life sciences sector to his new role.

What is the significance of Dr. Eric Poma’s appointment?

Dr. Poma’s extensive experience is expected to significantly contribute to the development and advancement of Calidi’s proprietary groundbreaking therapies, reinforcing the company’s commitment to innovation in cancer treatment.

Who did Dr. Eric Poma succeed as CEO?

Dr. Poma succeeds Allan Camaisa, who will continue to serve as a board member of Calidi Biotherapeutics Inc.

What does research say about the impact of experienced leadership on company performance?

Research indicates that companies with strong leadership are 2.3 times more likely to outperform their competitors financially, underscoring the importance of Dr. Poma’s appointment.

Where can investors find the latest news and updates about Calidi Biotherapeutics Inc.?

Investors can find the latest news and updates relating to CLDI in the company’s newsroom at https://ibn.fm/CLDI.

What is BioMedWire’s role in the biotechnology sector?

BioMedWire is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, providing companies with access to a vast network for press release distribution and brand awareness.

How can companies benefit from BioMedWire’s services?

Companies can benefit from BioMedWire’s services through access to a vast network of wire solutions, article and editorial syndication, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions, ensuring maximum impact and brand awareness.